The present invention is directed to itaconic acid derivatives, compounds comprising the derivatives and methods of using the derivatives in the treatment of cancer, inflammation, and autoimmune diseases.
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07C 57/42 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
2.
Compositions and methods of treatment using a BCAT1 inhibitor
C07C 255/21 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
The present invention is directed to BCAT inhibitors with the following formula:
+ denotes a cation. These inhibitors are useful in treating autoimmune inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.
The present invention is directed to methods of using inhibitors of the cytosolic form of BCAT in the treatment of cancer, rheumatoid arthritis, and bone disease.
patents
